• In the past quarter, PROCEPT BioRobotics reported strong third-quarter 2025 execution and issued fiscal 2026 revenue expectations of US$410 million to US$430 million, while management detailed organizational changes to accelerate new account launches and boost therapy awareness.
• Beyond the headline numbers, the company’s emphasis on improving procedure utilization to unlock longer-term value highlights how management is targeting deeper engagement within its existing customer base rather than relying solely on new system placements.
• With management now projecting US$410 million to US$430 million in 2026 revenue, we’ll examine how this updated outlook reshapes PROCEPT’s investment narrative.

Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 28 best rare earth metal stocks of the very few that mine this essential strategic resource.

PROCEPT BioRobotics Investment Narrative Recap

To own PROCEPT BioRobotics, you need to believe Aquablation can keep gaining share in benign prostatic hyperplasia while procedure volumes and utilization trends support a path toward lower losses over time. The latest third quarter 2025 update, with 2026 revenue expected at US$410 million to US$430 million, reinforces the near term catalyst of higher procedure utilization, but does little to lessen the key risk that adoption could still fall short if hospitals or surgeons hesitate to make Aquablation routine.

Among recent developments, the European Association of Urology’s upgrade of Aquablation to a strong recommendation for benign prostatic hyperplasia stands out here, because it directly supports the same utilization and adoption story management is prioritizing in its new guidance. That endorsement, alongside prior real world data and expanding HYDROS placements, ties closely to the near term catalyst of deeper engagement within existing accounts and may influence how investors weigh adoption risk against the company’s higher 2026 revenue outlook.

But while the growth story is appealing, investors should also be aware of how reimbursement pressure and shifting procedure settings could affect...

PROCEPT BioRobotics' narrative projects $586.6 million revenue and $76.8 million earnings by 2029. This requires 23.9% yearly revenue growth and a $172.4 million earnings increase from -$95.6 million today.

Uncover how PROCEPT BioRobotics' forecasts yield a $30.44 fair value, a 19% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were already modeling revenue of about US$624 million and positive earnings by 2029, so this new guidance and utilization focus could either support that bullish view or challenge it, depending on how you see the risk that hospital focused capital sales might be squeezed by reimbursement cuts and a gradual shift toward outpatient settings.

Explore 6 other fair value estimates on PROCEPT BioRobotics - why the stock might be worth just $30.44!

Decide For Yourself

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your PROCEPT BioRobotics research is our analysis highlighting 1 key reward and 2 important warning signs that could impact your investment decision.
• Our free PROCEPT BioRobotics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate PROCEPT BioRobotics' overall financial health at a glance.

No Opportunity In PROCEPT BioRobotics?

Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

• Explore 25 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
• We've uncovered the 11 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• Uncover the next big thing with 29 elite penny stocks that balance risk and reward.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.